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Abstract
Background: Chronic lung disease is common and often under-diagnosed.
Methods: To test a simple rule for conducting spirometry we reviewed spirograms from two populations,
occupational medicine evaluations (OME) conducted by Saint Louis and Wake Forest Universities at 3 sites (n = 3260,
mean age 64.14 years, 95 % CI 58.94–69.34, 97 % men) and conducted by Wake Forest University preop clinic (POC) at
one site (n = 845, mean age 62.10 years, 95 % CI 50.46–73.74, 57 % men). This retrospective review of database
information that the first author collected prospectively identified rates, types, sensitivity, specificity and positive and
negative predictive value for lung function abnormalities and associated mortality rate found when conducting
spirometry based on the 20/40 rule (≥20 years of smoking in those aged≥ 40 years) in the OME population. To
determine the reproducibility of the 20/40 rule for conducting spirometry, the rule was applied to the POC population.
Results: A lung function abnormality was found in 74 % of the OME population and 67 % of the POC population.
Sensitivity of the rule was 85 % for an obstructive pattern and 77 % for any abnormality on spirometry. Positive and
negative predictive values of the rule for a spirometric abnormality were 74 and 55 %, respectively. Patients with an
obstructive pattern were at greater risk of coronary heart disease (odds ratio (OR) 1.39 [confidence interval (CI) 1.00–1.
93] vs. normal) and death (hazard ratio (HR) 1.53, 95 % CI 1.20–1.84) than subjects with normal spirometry. Restricted
spirometry patterns were also associated with greater risk of coronary disease (odds ratio (OR) 1.7 [CI 1.23–2.35]) and
death (Hazard ratio 1.40, 95 % CI 1.08–1.72).
Conclusions: Smokers (≥ 20 pack years) age≥ 40 years are at an increased risk for lung function abnormalities and
those abnormalities are associated with greater presence of coronary heart disease and increased all-cause mortality.
Use of the 20/40 rule could provide a simple method to enhance selection of candidates for spirometry evaluation in
the primary care setting.
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Background
Spirometry is an important tool for assessing lung function
and the development of mobile, accurate and less expen-
sive equipment has allowed the assessment of spirometry
in primary care settings [1–3]. However, spirometry testing
remains underutilized in primary care [4, 5], perhaps due
to the lack of clarity of when to use spirometry evaluation.
Universal spirometry screening has been assessed for im-
proved Chronic Obstructive Pulmonary Disease (COPD)
diagnoses and found to be too expensive, requiring test-
ing of up to 465 individuals to deter one COPD
exacerbation [6]. Guidance is required to select an ap-
propriate subset of the general population in whom to
complete spirometry testing.
But smokers are at increased risk for a variety of abnor-
malities of lung function, not just COPD and lung func-
tion abnormalities have been reported in more than half
of current smokers [7]. Risk for, and under-detection of,
pulmonary function abnormalities, increase with increas-
ing age [8]. Pulmonary function abnormalities are markers
for increased morbidity and mortality [8–15]. Despite this
association pulmonary function abnormalities frequently
go undetected in clinical practice [4, 16–18].
Selective use of spirometry has been directed primarily
toward identification of individuals with undiagnosed
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COPD. For example, Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) suggests spirometric testing
for COPD identification based on age > 40 years and risks,
such as smoking history, or symptoms [19]. The American
College of Physicians recommends testing based on pres-
ence of both smoking history and symptoms, such as
cough, dyspnea, or wheeze, for testing [20]. This requires
collection of new clinical information that may not be in
the existing medical records nor volunteered by the patient.
Conversely, all medical records should include the pa-
tient’s age and smoking status. We present data on the
use of a simple rule that includes only the patient’s age
and smoking history to determine the need for spirom-
etry to detect lung abnormalities including those beyond
the obstructive patterns most consistent with COPD. In
addition, we assess the mortality risk associated with the
identified lung abnormalities [8–13].
Methods
Study populations
The OME group included workers screened for occupa-
tion lung disease conducted by Saint Louis and Wake For-
est Universities at 3 sites. Details of a portion of this
population have been reported previously [21]. Criteria for
occupational medical evaluation (OME) was occupational
exposure to asbestos that was at least 10 years prior to
evaluation and the possibility of an abnormal chest x-ray
(i.e., the presence of pleural plaque or International Labor
Union scoring of 0/1 or above). Data came from retro-
spective review of clinical data and pulmonary function
testing acquired 1983–2010 that was housed in a data re-
pository. Only subjects with a complete set of data were
used. All individuals had a brief history, chest radiograph
and pulmonary function testing. The history included ask-
ing subjects if a healthcare professional had ever given
them a diagnosis of chronic obstructive pulmonary dis-
ease, asthma, or heart disease including angina, myocar-
dial infarction or coronary heart disease. Subjects were
included in the analysis regardless of whether they were
previously diagnosed with COPD, asthma or not. Details
of the reliability of symptoms and clinical diagnosis of
COPD in a portion of this population have previously
been published (21). Cigarette smoking history (never,
former or current) was further quantified by pack-years
and a chest radiograph was completed for each patient.
Based on published chronic obstructive pulmonary disease
demographics [22], enrollment was limited to individuals
age ≥ 40 years without evidence of significant work related
chest x-ray abnormalities. This protocol was reviewed and
approved by the Saint Louis University and Wake Forest
University Institutional Review Boards (IRB) prior to the
initiation of the study.
To determine the reproducibility of the 20/40 rule for
conducting spirometry, the rule was applied to a population
of current or former smokers, 40 years of age and older,
who had smoked 20 or more pack years, seen in the pre-
operative clinic (POC) before elective surgery, at Wake
Forest University Baptist Medical Center. Subjects were
evaluated with spirometry from October 2013 to July 2014.
Pulmonary function testing
Pulmonary function testing was performed by respira-
tory therapists and a registered nurse, according to ATS
guidelines [23]. Spirometers (a Collins CPL at the 2
Wake Forest OME sites, Medgraphics at the Wake For-
est POC site and a Puritan Bennett Renaissance at the
Saint Louis University OME site) were all calibrated
daily. All forced vital capacity (FVC) maneuvers lasting
less than six seconds were discarded. Spirometric data
were expressed as percent predicted using National
Health and Nutrition Examination Survey (NHANES)
III predicted equations [24]. Airflow obstruction was de-
fined as a ratio of pre-bronchodilator FEV1 / FVC < 70 %
(forced expiratory volume in one second/forced vital
capacity) derived from modification of National Institute
for Clinical Excellence (NICE) [25] and Global Initiative
for Chronic Obstructive Lung Disease (GOLD) recom-
mendations necessary since post-bronchodilator testing
was not available [26]. Spirometry was classified into
four patterns according to the following definitions:
 Normal - FEV1/FVC ≥ 70 % and FEV1 > 80 % and
FVC > 80 %
 Obstructed - FEV1/FVC < 70 % and FEV1 ≤ 80 %
 Restricted - FEV1/FVC ≥ 70 % and FVC ≤ 80 %
 Unclassified - all others
Coronary heart disease history
Subjects from the OME population were asked if they
had a history of a myocardial infarction, coronary artery
stent, percutaneous transluminal coronary angioplasty
(PTCA), or coronary artery bypass grafting. An affirma-
tive response was considered positive evidence for self-
reported coronary heart disease. Odds ratio for coronary
heart disease was calculated by logistic regression.
Survival
Date of death for subjects from the OME group was de-
termined through a search of the social security death
database as of May 2012. Subjects not appearing on the
social security death database were assumed to be alive.
An adjusted survival analysis (Cox Proportional Hazards
regression) was run on the deceased subset. Data was
adjusted for age at the time of spirometric testing, cor-
onary heart disease, asthma, COPD and smoking status
(current, former or never).
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Statistical measures
Participant characteristics were compared across spirom-
etry groups (normal, obstructed, and restricted) using ei-
ther chi-square tests of association or one-way Analysis of
Variance (ANOVA), as appropriate. Sensitivity, specificity,
positive and negative predictive values and ROC curve
were determined. All analyses were completed using SAS
version 9.2 (SAS Institute, Inc., Cary, NC). Bonferroni
corrections were made for multiple statistical testing. A p-
value of 0.05 or less was considered statistically significant.
Availability of data and materials
According to the terms of approval of the Wake Forest
University IRB, data can be published without written
expressed consent from patients, if it is published in an
aggregated form, without patient identifiers. However, if
each patient’s data is to be shared publicly, there is the
possibility of patient identification and would warrant a
signed informed consent. Unique patient data is there-
fore not available in a publicly accessible repository.
Results
Prevalence of spirographic abnormalities when applying
the 20/40 algorithm
In the OME group, spirograms were performed on indi-
viduals 40 years of age and older (n = 3260); 2222 indi-
viduals met algorithm criteria of ≥ 40 years of age and
smoking history of at least 20 pack/years (Fig. 1). Of the
2222 spirograms that met ATS criteria for evaluation,
174 fell into the unclassified category. Of the remaining
2048 spirograms in this population, 815 (39.8 %) were
consistent with an obstructed pattern, 701 (34.2 %) with
a restrictive pattern, and 532 (26.0 %) were normal. Age,
pack-years smoked, and body mass index (BMI) all dif-
fered significantly among the individuals in the three
spirometric groups (Table 1). In general, the obstructed
group was the oldest, had the highest rate of pack years
of smoking, and was most likely to be current smokers
with the restrictive group intermediate and the group
with normal spirometry being the youngest and with the
fewest pack years. The pattern for the BMI was slightly
different with the highest average BMI in the restrictive
group and the lowest in the obstructive group with those
having normal spirometry intermediate. There was no
significant difference in gender among the three groups,
but men dominated the cohort by virtue of the method
of recruitment.
Self-reported coronary heart disease in subjects with
abnormal spirometry (obstruction versus restriction)
The prevalence of self-reported coronary heart disease
was greater (chi-square, p < 0.0002) in both the restricted
(20.5 %) and obstructed (17.9 %) groups, compared to
the normal spirometry group (12.0 %). Adjusting for
BMI, smoking in pack years and age the odds ratio (OR)
for having, self-reported coronary heart disease was sig-
nificantly greater for individuals with restrictive (OR
1.70, 95 % confidence interval 1.23–2.35) and individuals
with obstructive (OR1.39, 95 % confidence interval
1.00–1.93) spirometry patterns compared to those with
normal spirometry. There was no significant difference
in probability of coronary heart disease in the individuals
with obstructive patterns compared to those with re-
strictive patterns, OR 1.22 (0.93–1.60).
Survival of subjects with abnormal spirometry
Of the 2048 individuals available for analysis, e.g., those
having obstructive or restrictive or normal spirometry pat-
terns; 998 (48.7 %) died. Survival was significantly different
between those with normal and abnormal spirometry pat-
terns but not between those with the restrictive and the
obstructive patterns. The hazard ratio (HR) for death for
the restrictive pattern group (compared to the normal
group) was 1.40, 95 % CI 1.08–1.72, indicating that the re-
stricted group was at a 39.5 % higher risk of death than
the normal group. Similarly, the HR for the obstructive
pattern group was 1.53, 95 % CI 1.20–1.84 indicating a
52.7 % greater risk of death than the normal group.
Symptoms and self-report of obstructive lung disease
There was a significant difference in reporting of respira-
tory symptoms among the three groups (Table 2). Subjects
in the obstructive pattern group reported the highest rates
of wheeze, cough, shortness of breath, and sputum pro-
duction followed by those in the restrictive pattern group
and then those with normal spirometry (p < 0.001).
Based on self-report, among those patients with an ob-
structive spirometry pattern, 37.3 % had received a diag-
nosis of COPD alone with a further 9.5 % reporting a
Fig. 1 Of the 3260 spirograms evaluated in subject 40 years of age and
older, 232 were unclassifiable. Spirographic pattern (obstructed, restricted
or normal) is shown for the remaining 3028 grouped according to
smoking history
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diagnosis of asthma and COPD, now labeled as ACOS
(asthma-COPD overlap syndrome) [27] and 16.6 %
reporting a diagnosis of asthma alone. A COPD diagno-
sis was also reported by 19.1 % of those with a restrictive
spirometry pattern and by 11.3 % of those with a normal
spirometry result.
Sensitivity, specificity, positive and negative predictive
value
The 20/40 rule was highly sensitive for obstructed spir-
ometry with 86 % (95 % confidence interval 84–88 %)
sensitivity (Table 3). Sensitivity of the algorithm for any
spirometric abnormality (either obstructive or restrict-
ive) was 77 % (confidence interval 75–79 %) The algo-
rithm had a positive predictive value for any abnormality
(either obstructive or restrictive) of 74 % (confidence
interval 72–80 %).
20/40 rule replication
There were 845 spirograms performed in the POC
group. 98 failed to have three replicate loops greater
than six seconds, and 74 were unclassifiable, based on
our operational definitions, leaving 673 (79.6 %) for in-
terpretation. Despite the addition of women in the POC
group compared with the OME group, and a higher
percent of current smokers, the percent of abnormal
spirograms was similar in the POC group compared
with the OME group (Table 4). Sixty-seven percent were
abnormal, 38.3 % (258) with obstructive patterns, 28.4 %
(191) with restrictive patterns, and 33.3 % (224) with
normal spirometry.
Discussion
Main findings
Using a simple 20/40 rule based solely on age and smok-
ing history identifies a high percent of individuals (74 %
in the initial population and 67 % in the POC group)
with lung function abnormalities (both obstructive and
restrictive spirometry patterns). Further those meeting
the 20/40 rule who have lung function abnormalities
have an increased risk of all-cause mortality and a high
rate of reported coronary heart disease, compared to in-
dividuals with normal spirometry.
Using the simple 20/40 rule in primary care could fa-
cilitate the appropriate use of spirometry evaluation and
support the diagnosis of COPD in up to 40 % of patients
with limited need for further testing. This spirometry
testing could be accomplished in the primary care office
[28–30] allowing rapid diagnosis and initiation of appro-
priate COPD management. For the 30 % of individuals
Table 1 Subject characteristics – Occupational medical evaluation group
Normal
(n = 532)
Obstructed
(n = 815)
Restricted
(n = 701)
Significance
FEV1 % predicted [mean (SD)] 94.3 (8.8) 53.6 (16.3) 70.7 (11.6) P < 0.001
FVC % predicted [mean (SD)] 92.4 (8.5) 70.4 (15.7) 67.7 (10.5) P < 0.001
FEV1/FVC [mean (SD)] 77.0 (4.4) 56.3 (10.6) 78.3 (5.5) P < 0.001
Gender [n (%) Male] 513 (99.4) 795 (97.6) 674 (96.2) 0.1646
Current smoker [n (%)] 129 (24.3) 269 (33.0) 189 (27.0) P < 0.001
Obesity [n (%)] 191 (35.9) 211 (25.9) 339 (48.4) P < 0.001
BMI [mean (SD)] 29.3 (4.4) 27.9 (5.0) 30.5 (5.1) P < 0.001
Age [mean (SD)] 62.0 (9.1) 65.8 (8.5) 64.2 (9.2) P < 0.001
Pack years [mean (SD)] 46.0 (24.9) 58.8 (30.7) 51.9 (27.8) P < 0.001
Table 2 Self-report of symptoms and disease - occupational medical evaluation group
Normal (n = 532) Obstructed (n = 815) Restricted (n = 701) Significance
Wheeze [n (%)] 234 (44.0) 593 (72.8) 407 (58.1) p < 0.001
Cough [n (%)] 285 (53.6) 587 (72.0) 414 (59.1) p < 0.001
SOB [n (%)] 302 (56.8) 669 (82.1) 501 (71.5) p < 0.001
Sputum [n (%)] 195 (36.7) 455 (55.8) 281 (40.1) p < 0.001
# of Symptoms [mean (SD)] 1.9 (1.4) 2.8 (1.2) 2.3 (1.4) p < 0.001
Self-reported COPD [n (%)] 32 (6.0) 304 (37.3) 77 (11.0) p < 0.001
Self-reported asthma [n (%)] 25 (4.7) 135 (16.6) 43 (6.1) p < 0.001
Self-reported asthma & COPD [n (%)] 3 (0.6) 77 (9.5) 14 (2.0) p < 0.001
Self-reported CHD [n (%)] 64 (12.0) 146 (17.9) 144 (20.5) p < 0.001
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with a restrictive lung pattern, the addition of lung vol-
umes and perhaps other elements of full pulmonary
function testing may be required to determine the accur-
acy of the restrictive pattern and assess possible associ-
ated diagnoses.
Our evaluation of the 20/40 rule confirmed the previ-
ously reported over and under diagnosis of COPD within
this population. Of those who remembered receiving a
COPD or COPD plus asthma diagnosis, 11.3 % had nor-
mal spirometry assessment suggesting that a different
condition may be causing their symptoms—potential over
diagnosis. Conversely, 53.2 % of the individuals with an
obstructive pattern did not believe they had received a
COPD diagnosis (under diagnosis) likely prohibiting them
from receiving any of the therapies known to improve
symptom burden or prolong life [31].
Relationship to the literature
Use of the 20/40 rule goes beyond simply “screening” for
risk of COPD and includes the opportunity to evaluate
for the presence of restrictive spirometry patterns which
may also be seen with COPD or with other conditions in
the lungs and other organ systems. Spirometric results
from our study groups provide important new data on
rates of restrictive spirometry patterns in long-term
smokers. Published values for prevalence of a restricted
pattern on spirometry in unselected populations vary
from 10.3 to 12.3 % [8, 32]. Data from the Multi-Ethnic
Study of Atherosclerosis (MESA) [33] showed that
among smokers the prevalence of a restricted pattern on
spirometry was 10 %, increasing by 8 % (95 % confidence
interval 3–12 %) for each 10 pack-years smoked. The
prevalence of a restricted pattern in MESA was 16 % for
the > 20 pack year cohort, who had a smoking history
significantly lower than our OME group (36 pack years,
95 % CI 27–50 vs 51.9 ± 27.8 pack years). Allowing for
the additional increase in prevalence of restriction for
each pack year smoked found in MESA, the 28.4 and
34.2 % prevalence of restrictive spirometry in our study
populations is consistent with the MESA data and
provides a useful population estimate in longer-term
smokers aged 40 years and older.
Under recognition of lung function abnormalities in
smokers is common. But most studies focus on the air-
flow obstruction reported to occur in up to 50 % of
long-term smokers [34] for which under recognition is
well documented [4, 16, 17]. However, the under-
recognition of a restricted pattern in smokers is less well
studied, but is clearly evident from our results which
also highlights the potential consequences of under-
recognition of both obstructive and restrictive lung func-
tion abnormalities. With airflow obstruction, these
consequences include under treatment, that may lead to
increased exacerbation frequency, symptoms, decreased
quality of life, and increased medical costs [35]. Restrict-
ive spirometry patterns are also seen in smoking related
conditions such as fibrotic interstitial lung disease,
(RBILD or respiratory bronchiolitis with interstitial lung
disease) [10, 36] muscle weakness [11], heart disease
[12], obesity and the metabolic syndrome [13]. A re-
stricted spirometry pattern has been reported to be asso-
ciated with numerous cigarette and non-cigarette related
co-morbidities, including hypertension, type II diabetes,
atherosclerosis, cardiovascular disease, and all-cause
mortality, in a manner that is statistically independent of
confounding variables, such as diabetes, obesity, and
Table 3 Sensitivity, specificity, positive and negative predictive values for OME group
Sensitivity
(%)
Specificity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Disease
prevalence
(%)
Positive
Likelihood
Ratio
Negative
Likelihood
Ratio
For obstruction 85 (84–88) 41 (39–43) 40 (38–42) 86 (84–89) 31 (30–33) 1.45 (1.39–1.52) 0.34 (0.29–0.41)
For any spirometry abnormality
(obstruction + restriction)
77 (75–79) 50 (47–53) 74 (72–80) 55 (51–58) 65 (63–66) 1.55 (1.45–1.65) 0.45 (0.41–0.50)
Values listed with (95 % confidence interval) OME - occupational medical evaluation
Table 4 Subject characteristics – Algorithm replication population
Normal
n = 224
Obstructed
n = 258
Restricted
n = 191
FEV1 % predicted [mean (SD)] 94.84 (9.51) 56.20 (13.85) 70.52 (10.00)
FEV1 (L)(± SD) 2.79 (0.65) 1.73 (0.56) 2.14 (0.57)
Sex (% male vs. female) 50 vs. 50 71 vs. 29 52 vs. 48
Smoke Status (Current vs. Past) 58 vs. 42 65 vs. 35 58 vs. 42
BMI [mean (SD)] 30.06 (6.75) 27.01 (6.25) 31.65 (7.19)
Age [mean (SD)] 59.90 (9.68) 65.41 (10.73) 61.09 (9.60)
Pack years [mean (SD)] 48.10 (43.89) 59.55 (36.81) 50.90 (46.88)
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smoking history [37–47]. Our data shows that the preva-
lence of coronary heart disease and all-cause mortality is
significantly greater for smokers age ≥ 40 years with a re-
stricted pattern than for those with normal spirometry. In
fact, there was no significant difference in coronary heart
disease prevalence and all-cause mortality, between
subjects with an obstructed and those with a restricted
pattern on spirometry. Under-recognition of both ob-
struction and restriction in smokers, age ≥ 40 years, is a
common occurrence with significant health consequences.
Other approaches have been developed for selecting
patients at high risk of airflow limitation. These include
use of questionnaires [48–52], risk prediction models
[53] and handheld flow meters [54, 55]. Most question-
naires developed for COPD are related to patient out-
comes of quality of life. The COPD population screener
(COPD-PS) is a 5 question tool with a positive predictive
value of 56.8 % and negative predictive value of 86.4 %
[50]. van Schayck et al. [52] and Calverley et al. [56] de-
veloped a population-based screening questionnaire for
COPD using NHANES III data. Price and coworkers
[51] published an 8-item COPD questionnaire in pa-
tients with a positive smoking history that included
items related to age group, body mass index, pack-year
history, and symptoms. Finally, Freeman and colleagues
[57] utilized age, cough, dyspnea, and wheezing in a
questionnaire to identify patients with COPD in a pri-
mary care setting who had a positive smoking history,
history of respiratory medication use, or of asthma. The
COPD-PS differs from these previous questionnaires be-
cause it can be used regardless of history of respiratory
problems or smoking and it contains a disease-impact
item. Population screeners when used in combination
with peak expiratory flow measurement (PEF) however
have been shown to add little to PEF alone [54, 58, 59].
A new questionnaire developed by the High Risk-COPD
Screening Group is currently undergoing testing in com-
bination with PEF [60]. Preliminary data is impressive
[61]. A single published risk prediction model utilizing
sex, socioeconomic status and previously recorded
asthma diagnosis has performed well in an initial deriv-
ation cohort of 480,903 and validation cohort of
247,755 subjects with area under the receiver operating
curve of 0.8 [53].
Strengths and limitations
Limitations in this study include the use of a fixed thresh-
old cut-off for the definition of obstruction (FEV1/FVC <
70 %). This fixed ratio threshold has been demonstrated to
introduce age related bias [62]. Use of a fixed ratio can re-
sult in misclassification in more than 1/4th of tests [63] and
over diagnosis of airflow obstruction in older subjects [64].
However, the further qualification of FEV1 < 80 % placed
on our obstruction definition reduces over diagnosis
significantly [65]. FVC and FEV1 were assessed before
bronchodilator, allowing the possibility that a portion of the
obstructed spirometries might display reversibility, suggest-
ive of a purely asthmatic component, rather than chronic
obstructive pulmonary disease [66].
Implications for policy, practice and research
The goal of this study was to increase use of spirometry
in the primary care setting. Only half of primary care
providers routinely use spirometry in their practice of
medicine [67]. Among primary care physicians spirom-
etry use was associated with agreeing that the data are
necessary for accurate diagnosis, and believing that they
were trained to perform and interpret the test [68]. In
view of these reports and others, we elected to use a
simple rule that might increase use of spirometry in the
primary care setting without significantly sacrificing ac-
curacy. We wanted to show that use of this simple rule
could enhance diagnostic yield that had a clinical impact
such as increased risk for CHD and death. Furthermore,
it distinguished individuals that would benefit from lung
volume measurement. Using the 20/40 rule resulted in
detection of an abnormality on spirometry in nearly
70 % of individuals tested.
Conclusion
We show this simple 20/40 rule, based solely on age and
smoking history performs well in predicting pulmonary
function abnormalities. Sensitivity of the algorithm was
85 % for an obstructive pattern and 77 % for any abnor-
mality on spirometry. Positive and negative predictive
values for any spirometric abnormality were 74 and
55 %, respectively. Furthermore, we show that pulmon-
ary function abnormalities, which are often under-
recognized, are associated with coronary heart disease
and all-cause mortality and might prompt further valu-
able clinical evaluations. Using an easily applied 20/40
rule based on information that should be available in all
medical records, age 40 years or greater and 20 or more
years of smoking can simplify the decision of when and
with whom to complete spirometry. The results provide
clinically significant information for the diagnosis of not
only COPD but identification of restrictive lung patterns
both of which are associated with increased mortality
risk. The 20/40 rule is a simple, sensitive, predictor of
lung function abnormalities that are markers for COPD,
coronary heart disease and all-cause mortality.
Under diagnosis of chronic lung disease is common.
NHANES estimates that >50 % of individuals with air-
flow obstruction are undiagnosed [4]. Preliminary data
suggests that diagnosis of chronic lung disease is linked
to perception and report of symptoms. In a population
of screened individuals, matched for FEV1, subjects with
a diagnosis of COPD had greater symptom scores than
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those previously unrecognized as COPD [69]. Further-
more, subjects with unrecognized COPD experienced a
greater number of postoperative respiratory complica-
tions, than subjects diagnosed with COPD, despite similar
lung function [70]. These data would suggest that under
recognition of symptoms leads to under diagnosis of
chronic lung disease. But under recognition of symptoms
does not protect patients from the common respiratory
complications of surgery that their compromised lung
function causes, thus, making a case for selective use of
spirometry based on age and smoking history.
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